Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

by Wolfgang Schuette, Peter Schirmacher, Wilfried E. E. Eberhardt, Manfred Dietel, Ute Zirrgiebel, Lars Muehlenhoff, Michael Thomas
Published 2018-02-01

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition

by Maja Guberina, Kaid Darwiche, Hubertus Hautzel, Christoph Pöttgen, Nika Guberina, Thomas Gauler, Till Ploenes, Lale Umutlu, Dirk Theegarten, Clemens Aigner, Wilfried E. E. Eberhardt, Martin Metzenmacher, Marcel Wiesweg, Rüdiger Karpf-Wissel, Martin Schuler, Ken Herrmann, Martin Stuschke
Published 2021-09-01

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

by Sabrina Borchert, Michael Wessolly, Jan Schmeller, Elena Mairinger, Jens Kollmeier, Thomas Hager, Thomas Mairinger, Thomas Herold, Daniel C. Christoph, Robert F. H. Walter, Wilfried E. E. Eberhardt, Till Plönes, Jeremias Wohlschlaeger, Clemens Aigner, Kurt Werner Schmid, Fabian D. Mairinger
Published 2019-01-01

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53

by Robert F. H. Walter, Robert Werner, Michael Wessolly, Elena Mairinger, Sabrina Borchert, Jan Schmeller, Jens Kollmeier, Thomas Mairinger, Thomas Hager, Agnes Bankfalvi, Daniel C. Christoph, Wilfried E. E. Eberhardt, Till Plönes, Clemens Aigner, Kurt W. Schmid, Jeremias Wohlschlaeger, Fabian D. Mairinger
Published 2018-01-01